Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Summary

This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation. Giving drugs that target other genetic mutations or other specific proteins may work better when a patient has cancer caused by a driver mutation and the treatment that targets that mutation stops working.

Timeline

Start

2017-03-10

Primary completion

2018-01-08

Completion

2021-01-12

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual, closed by IRB”

Drugs

Indications